SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PRX-08066

Item No. 31477

CAS Registry No.:	866206-54-4
Formal Name:	5-[[4-[(6-chlorothieno[2,3-d] pyrimidin-4-yl)amino]-1-piperidinyl] methyl]-2-fluoro-benzonitrile
MF:	$C_{19}H_{17}ClFN_5S$
FW:	401.9
Purity:	≥95%
UV/Vis.:	λ_{max}: 221, 279 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PRX-08066 is supplied as a crystalline solid. A stock solution may be made by dissolving the PRX-08066 in the solvent of choice, which should be purged with an inert gas. PRX-08066 is soluble in ethanol and DMSO. The solubility of PRX-08066 in these solvents is approximately 91 and 96 mg/ml. It is also soluble in water. The solubility of PRX-08066 in water is approximately 95 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

PRX-08066 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT_{2B}.[1] It binds to 5-HT_{2B} receptors (K_i = 3.4 nM) and inhibits 5-HT-induced MAPK activation and thymidine incorporation in CHO cells expressing human 5-HT_{2B} (IC_{50}s = ~12 and ~3 nM, respectively). PRX-08066 (50 and 100 mg/kg) reduces peak pulmonary arterial pressure and right ventricular hypertrophy in a rat model of pulmonary hypertension induced by monocrotaline (MCT; Item No. 16666).

Reference

1. Porvasnik, S.L., Germain, S., Embury, J., *et al*. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. *J. Pharmacol. Exp. Ther.* **334(2)**, 364-372 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM